糖尿病治療薬の世界市場レポート 2025年

糖尿病治療の市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）11.3％で1,301億2,000万米ドルに成長します。予測期間の成長は、糖尿病有病率の増加、認知度・診断度の向上、医療支出の増加、高齢者の拡大、政府の取り組み、健康施策などに起因すると考えられます。予測期間における主要動向としては、GLP-1受容体作動薬とSGLT2阻害剤の成長、生物製剤とバイオシミラーの拡大、予防医療への注力、新興市場の成長、技術統合などが挙げられます。

糖尿病治療市場は、生活習慣に関連した疾患の有病率の増加により成長すると予測されます。生活習慣病とは、食生活の乱れ、運動不足、喫煙、過度の飲酒などの行動から生じる健康上の問題です。このような症状の増加は、不健康な食生活、運動不足、ストレスレベルの上昇に関連しています。抗糖尿病薬は、インスリン感受性を高め、血糖値をコントロールすることにより、肥満やメタボリックシンドロームといった生活習慣に関連した問題を管理することができます。例えば、世界保健機関（WHO）は2022年3月、6億5,000万人の成人、3億4,000万人の青年、3,900万人の小児を含む世界の約10億人が肥満であると報告しました。この数字は今後も増加すると予想され、2025年までに推定1億6,700万人の成人と幼児が、過体重または肥満による健康合併症に直面すると予測されています。このような生活習慣病の増加が、抗糖尿病市場の拡大を牽引しています。

糖尿病治療セグメントの企業は、血糖コントロールを改善し、心血管リスクを低減し、糖尿病管理により効果的な選択肢を提供するために、抗糖尿病バイオシミラーなどの先進治療の開発に注力しています。抗糖尿病バイオシミラーとは、すでに承認されている糖尿病治療の生物学的に類似したバージョンであり、同等の安全性、有効性、品質を記載しています。例えば、2024年1月、インドに本社を置くグレンマーク・ファーマシューティカルズ社は、抗糖尿病薬リラグルチドのバイオシミラー第1号を発表しました。リラフィットと名付けられたこのバイオシミラー医薬品は、成人の2型糖尿病患者の血糖コントロールを改善するよう設計されています。臨床検査では、血糖値の低下、体重減少のサポート、心血管安全性の向上が実証されています。GLP-1受容体作動薬として、グルコース依存性のインスリン分泌を促進し、不適切なグルカゴン分泌を減少させています。成人の2型糖尿病の治療として世界的に承認されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の糖尿病治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の糖尿病治療市場：成長率分析
• 世界の糖尿病治療市場の実績：規模と成長、2019～2024年
• 世界の糖尿病治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の糖尿病治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• インスリン
• GLP-1受容体作動薬
• DPP-4阻害剤
• SGLT2阻害剤
• その他
• 世界の糖尿病治療市場：糖尿病タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• タイプ1
• タイプ2
• 世界の糖尿病治療市場：患者集団別、実績と予測、2019～2024年、2024～2029年、2034年
• 糖尿病治療小児科向け
• 糖尿病治療成人向け
• 糖尿病治療高齢者医療
• 世界の糖尿病治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 糖尿病治療インスリン注射器またはインスリンペンによる投与
• 糖尿病治療インスリンポンプによる投与
• 静脈内糖尿病治療点滴
• 口頭糖尿病治療投与
• 糖尿病治療投与の他のルート
• 世界の糖尿病治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• オンライン薬局
• 病院薬局
• 小売薬局
• 世界の糖尿病治療市場、インスリンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 速効型インスリン
• 短時間作用型インスリン
• 中間型インスリン
• 長時間作用型インスリン
• 混合インスリン
• 世界の糖尿病治療市場、GLP-1受容体作動薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エキセナチド
• リラグルチド
• デュラグルチド
• セマグルチド
• リキシセナチド
• 世界の糖尿病治療市場、DPP-4阻害剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• シタグリプチン
• サクサグリプチン
• リナグリプチン
• アログリプチン
• 世界の糖尿病治療市場、SGLT2阻害剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カナグリフロジン
• ダパグリフロジン
• エンパグリフロジン
• エルツグリフロジン
• 世界の糖尿病治療市場、その他の薬剤クラスのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• スルホニル尿素
• チアゾリジンジオン（TZD）
• アルファグルコシダーゼ阻害剤
• メグリチニド
• GLP-1/インスリン併用療法

第7章 地域別・国別分析

• 世界の糖尿病治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の糖尿病治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病治療市場：競合情勢
• 糖尿病治療市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Bayer AG
  • Sanofi S.A.

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• Takeda Pharmaceutical Company Limited
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 糖尿病治療市場、2029年：新たな機会を提供する国
• 糖尿病治療市場、2029年：新たな機会を提供するセグメント
• 糖尿病治療市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Antidiabetics are medications designed to manage diabetes mellitus, a condition marked by elevated blood glucose levels. These drugs help control blood sugar through various mechanisms, tailored to the specific type of diabetes and drug action. They work to regulate blood sugar, lessen complications, enhance health outcomes, improve metabolic control and insulin sensitivity, offer personalized treatment, and provide additional benefits such as weight management and cardiovascular protection.

The primary classes of antidiabetics include insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. Insulin, a hormone produced by the pancreas, is crucial for regulating blood sugar levels. Diabetes is categorized into type 1 and type 2, with antidiabetics available for pediatric, adult, and geriatric patients. Antidiabetics can be administered through various routes, such as insulin syringes or pens, insulin pumps, intravenous infusions, or oral tablets, and are distributed through multiple channels including online pharmacies, hospital pharmacies, and retail pharmacies.

The antidiabetics market research report is one of a series of new reports from The Business Research Company that provides antidiabetics market statistics, including antidiabetics industry global market size, regional shares, competitors with a antidiabetics market share, detailed antidiabetics market segments, market trends and opportunities, and any further data you may need to thrive in the antidiabetics industry. This antidiabetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antidiabetics market size has grown rapidly in recent years. It will grow from $76.03 billion in 2024 to $84.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to rising global diabetes prevalence, advancements in drug development, increased awareness and diagnosis, supportive government policies, a growing geriatric population, sedentary lifestyles, and increasing healthcare expenditure.

The antidiabetics market size is expected to see rapid growth in the next few years. It will grow to $130.12 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, increasing awareness and diagnosis, rising healthcare expenditure, expanding geriatric population, government initiatives and health policies. Major trends in the forecast period include growth in GLP-1 receptor agonists and SGLT2 inhibitors, biologics and biosimilar expansion, focus on preventive healthcare, emerging market growth, and technological integration.

The antidiabetics market is anticipated to grow due to the increasing prevalence of lifestyle-related conditions. These conditions are health problems arising from behaviors such as poor diet, lack of exercise, smoking, and excessive alcohol consumption. The rise in such conditions is linked to unhealthy diets, physical inactivity, and heightened stress levels. Antidiabetic medications can manage lifestyle-related issues such as obesity and metabolic syndrome by enhancing insulin sensitivity and controlling blood sugar levels. For example, the World Health Organization reported in March 2022 that approximately 1 billion people worldwide, including 650 million adults, 340 million teenagers, and 39 million children, were obese. This figure is expected to rise, with an estimated 167 million adults and children projected to face health complications from being overweight or obese by 2025. This growing incidence of lifestyle-related conditions is driving the expansion of the antidiabetic market.

Companies in the antidiabetics sector are focusing on developing advanced treatments, such as anti-diabetic biosimilars, to improve glycemic control, reduce cardiovascular risk, and provide more effective options for diabetes management. An anti-diabetic biosimilar is a biologically similar version of an already approved diabetes drug, offering comparable safety, efficacy, and quality. For instance, in January 2024, Glenmark Pharmaceuticals Limited, based in India, introduced the first biosimilar of Liraglutide, an antidiabetic drug. This biosimilar, named Lirafit, is designed to improve glycemic control in adults with type 2 diabetes mellitus. Clinical trials have demonstrated that it reduces glycemic levels, supports weight loss, and enhances cardiovascular safety. As a GLP-1 receptor agonist, it promotes glucose-dependent insulin secretion and decreases inappropriate glucagon secretion. It is globally approved for managing type 2 diabetes in adults.

In August 2023, Lupin, an Indian pharmaceutical company, acquired the ONDERO and ONDERO MET brands from Boehringer Ingelheim International GmbH for an undisclosed amount. This acquisition is intended to strengthen Lupin's presence in the antidiabetic market and expand its product offerings. Boehringer Ingelheim International GmbH, a Germany-based company, specializes in antidiabetic medications.

Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

North America was the largest region in the antidiabetics market in 2024. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antidiabetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antidiabetics market consists of sales of pramlintide, thiazolidinediones, insulin glargine, and exenatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antidiabetics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antidiabetics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antidiabetics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antidiabetics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Insulin; GLP-1 Receptor Agonists; DPP- 4 Inhibitors; SGLT2 Inhibitors; Other Drug Classes,
• 2) By Diabetes Type: Type 1; Type 2
• 3) By Patient Population: Antidiabetics For Pediatrics; Antidiabetics For Adults; Antidiabetics For Geriatrics
• 4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens; Antidiabetics Administration Through Insulin Pumps; Intravenous Antidiabetics Infusion; Oral Antidiabetics Administration; Other Routes Of Antidiabetics Administration
• 5) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin
• 2) By GLP-1 Receptor Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide
• 3) By DPP-4 Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
• 4) By SGLT2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin
• 5) By Other Drug Classes: Sulfonylureas; Thiazolidinediones (TZDs); Alpha-Glucosidase Inhibitors; Meglitinides; GLP-1/Insulin Combination Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antidiabetics Market Characteristics

3. Antidiabetics Market Trends And Strategies

4. Antidiabetics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Antidiabetics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antidiabetics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antidiabetics Market Growth Rate Analysis
• 5.4. Global Antidiabetics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antidiabetics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antidiabetics Total Addressable Market (TAM)

6. Antidiabetics Market Segmentation

• 6.1. Global Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin
• GLP-1 Receptor Agonists
• DPP- 4 Inhibitors
• SGLT2 Inhibitors
• Other Drug Classes
• 6.2. Global Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• 6.3. Global Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidiabetics For Pediatrics
• Antidiabetics For Adults
• Antidiabetics For Geriatrics
• 6.4. Global Antidiabetics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidiabetics Administration Through Insulin Syringes Or Insulin Pens
• Antidiabetics Administration Through Insulin Pumps
• Intravenous Antidiabetics Infusion
• Oral Antidiabetics Administration
• Other Routes Of Antidiabetics Administration
• 6.5. Global Antidiabetics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• 6.6. Global Antidiabetics Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rapid-Acting Insulin
• Short-Acting Insulin
• Intermediate-Acting Insulin
• Long-Acting Insulin
• Premixed Insulin
• 6.7. Global Antidiabetics Market, Sub-Segmentation Of GLP-1 Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exenatide
• Liraglutide
• Dulaglutide
• Semaglutide
• Lixisenatide
• 6.8. Global Antidiabetics Market, Sub-Segmentation Of DPP-4 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin
• 6.9. Global Antidiabetics Market, Sub-Segmentation Of SGLT2 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Canagliflozin
• Dapagliflozin
• Empagliflozin
• Ertugliflozin
• 6.10. Global Antidiabetics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sulfonylureas
• Thiazolidinediones (TZDs)
• Alpha-Glucosidase Inhibitors
• Meglitinides
• GLP-1/Insulin Combination Therapy

7. Antidiabetics Market Regional And Country Analysis

• 7.1. Global Antidiabetics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antidiabetics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antidiabetics Market

• 8.1. Asia-Pacific Antidiabetics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antidiabetics Market

• 9.1. China Antidiabetics Market Overview
• 9.2. China Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antidiabetics Market

• 10.1. India Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antidiabetics Market

• 11.1. Japan Antidiabetics Market Overview
• 11.2. Japan Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antidiabetics Market

• 12.1. Australia Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antidiabetics Market

• 13.1. Indonesia Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antidiabetics Market

• 14.1. South Korea Antidiabetics Market Overview
• 14.2. South Korea Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antidiabetics Market

• 15.1. Western Europe Antidiabetics Market Overview
• 15.2. Western Europe Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antidiabetics Market

• 16.1. UK Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antidiabetics Market

• 17.1. Germany Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antidiabetics Market

• 18.1. France Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antidiabetics Market

• 19.1. Italy Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antidiabetics Market

• 20.1. Spain Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antidiabetics Market

• 21.1. Eastern Europe Antidiabetics Market Overview
• 21.2. Eastern Europe Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antidiabetics Market

• 22.1. Russia Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antidiabetics Market

• 23.1. North America Antidiabetics Market Overview
• 23.2. North America Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antidiabetics Market

• 24.1. USA Antidiabetics Market Overview
• 24.2. USA Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antidiabetics Market

• 25.1. Canada Antidiabetics Market Overview
• 25.2. Canada Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antidiabetics Market

• 26.1. South America Antidiabetics Market Overview
• 26.2. South America Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antidiabetics Market

• 27.1. Brazil Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antidiabetics Market

• 28.1. Middle East Antidiabetics Market Overview
• 28.2. Middle East Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antidiabetics Market

• 29.1. Africa Antidiabetics Market Overview
• 29.2. Africa Antidiabetics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antidiabetics Market, Segmentation By Diabetes Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antidiabetics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antidiabetics Market Competitive Landscape And Company Profiles

• 30.1. Antidiabetics Market Competitive Landscape
• 30.2. Antidiabetics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Antidiabetics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. GSK plc
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Gilead Sciences Inc.
• 31.11. Novo Nordisk A/S
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Regeneron Pharmaceuticals Inc.
• 31.14. Astellas Pharma Inc.
• 31.15. Biogen

32. Global Antidiabetics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antidiabetics Market

34. Recent Developments In The Antidiabetics Market

35. Antidiabetics Market High Potential Countries, Segments and Strategies

• 35.1 Antidiabetics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antidiabetics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antidiabetics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer